WebDoctor Encyclopedia

Cervical

Small cell neuroendocrine carcinoma of the cervix

Small cell neuroendocrine carcinoma of the cervix is a rare, fast-growing HPV-related cervical cancer that behaves like small cell lung cancer. It spreads early, so treatment combines etoposide-platinum chemotherapy with surgery or radiotherapy.

Medically reviewed Last reviewed October 21, 2026

What is small cell neuroendocrine carcinoma of the cervix?

Small cell neuroendocrine carcinoma of the cervix is a rare and aggressive type of cervical cancer. The cervix is the lower, narrow part of the womb that opens into the vagina. In this cancer, the tumour cells are small and behave like neuroendocrine cells, cells that share features with both nerve cells and hormone-producing cells.

The disease looks and behaves much like small cell lung cancer. It grows fast and tends to spread early through the blood and lymph vessels to lymph nodes, the lungs, liver, bones and brain. For that reason, treatment usually combines chemotherapy with surgery or radiotherapy, even when the cancer seems to be confined to the cervix.

Neuroendocrine carcinomas make up only about 1-2% of all cervical cancers. Most of them, about four in five, are of the small cell type (Tempfer et al., 2018). Like common cervical cancer, it is usually linked to human papillomavirus (HPV) infection (Chao et al., 2023).

How it differs from common cervical cancer

Most cervical cancers are squamous cell carcinomas or adenocarcinomas, described on our page on cervical cancer. Small cell neuroendocrine carcinoma shares the HPV link but differs in important ways.

Feature Squamous cell carcinoma or adenocarcinoma Small cell neuroendocrine carcinoma
Share of cervical cancers The vast majority About 1%
Growth Often slower Very fast
Spread Often stays in the pelvis for a long time Early spread to distant organs
Screening Often found early by smear tests Smear tests may miss it
Chemotherapy Cisplatin with radiotherapy Etoposide plus platinum, as in small cell lung cancer
Outlook Good for early stages Guarded even in early stages

1. Key facts at a glance

Feature Details
Type of cancer High-grade neuroendocrine carcinoma of the cervix
How common About 1% of cervical cancers
Typical age Often women in their 30s to 50s
Main cause HPV infection, especially HPV type 18
Usual first sign Abnormal vaginal bleeding
Spread Lymph nodes, lungs, liver, bone and brain
Main treatments Etoposide-platinum chemotherapy with surgery or chemoradiotherapy
Outlook Guarded; better when found at an early stage

2. Types

Neuroendocrine tumours of the cervix

Type Description Share
Small cell neuroendocrine carcinoma Small cells with scant cytoplasm About 80% of cervical neuroendocrine carcinomas
Large cell neuroendocrine carcinoma Larger cells with more cytoplasm About 12%
Mixed carcinoma Neuroendocrine carcinoma together with adenocarcinoma or squamous cancer A minority
Neuroendocrine tumour (carcinoid) Well-differentiated; very rare in the cervix Rare

The proportions come from a large systematic review of more than 3,500 cases (Tempfer et al., 2018).

3. Causes and risk factors

Factor Notes
HPV infection Found in most tumours; HPV 18 is the most frequent type
Smoking Raises the risk of cervical cancer in general
Weakened immunity Such as HIV infection, which makes HPV harder to clear
Lack of screening and vaccination Increases the risk of all HPV-related cervical cancers
Inherited factors No known inherited syndrome

Why does it spread so early?

Small cell carcinomas divide very rapidly and readily invade small blood vessels and lymph channels. Tumour cells can therefore reach distant organs while the tumour in the cervix still looks small. This is why chemotherapy that treats the whole body is part of treatment for almost every woman with this cancer.

Can the HPV vaccine prevent it?

Because most of these cancers are caused by high-risk HPV types that are covered by current vaccines, HPV vaccination is expected to reduce this cancer as well as common cervical cancer.

4. How does it look

On examination

Finding Description
Cervix A visible mass, ulcer or bleeding area; sometimes the cervix looks enlarged and firm
Inside the canal Tumours may grow inside the cervical canal and be hard to see
Pelvic examination May show spread to the vagina or the tissues beside the womb

On scans

Scan Purpose
Pelvic MRI Shows the size of the tumour and spread into nearby tissues
CT or PET-CT Checks lymph nodes and distant organs
Brain MRI Considered by some teams, as brain spread is more frequent than with common cervical cancer

Under the microscope

Feature Description
Cells Small, round to oval cells with very little cytoplasm
Nuclei Finely granular chromatin, nuclei moulding against each other
Activity Many dividing cells and areas of cell death
Neuroendocrine markers Synaptophysin, chromogranin, CD56 and INSM1
Proliferation Very high Ki-67 index
HPV testing Usually positive for high-risk HPV

In the systematic review, synaptophysin was the marker most often positive, in about four of five tested tumours (Tempfer et al., 2018).

5. Symptoms

Common symptoms

  • Bleeding after sex
  • Bleeding between periods or after the menopause
  • Unusual vaginal discharge, which may be watery, blood-stained or smelly
  • Pain in the pelvis

Less common symptoms

Symptom Possible cause
Back or leg pain, leg swelling Spread to pelvic or abdominal lymph nodes
Difficulty passing urine or opening bowels Pressure from a large tumour
Cough or breathlessness Spread to the lungs
Bone pain Spread to bone
Headaches, confusion or seizures Spread to the brain
Flushing, low sodium or other hormone effects Rare hormone release by the tumour

When to seek medical advice

See a doctor about any unexplained vaginal bleeding, especially after sex or after the menopause. Do not wait for your next screening test, as smear tests can miss this cancer.

6. Diagnosis

Step What is done
Pelvic examination Checks the cervix and nearby tissues
Colposcopy and biopsy Takes tissue from the cervix
Pathology with neuroendocrine stains Confirms the diagnosis
Pelvic MRI Measures local spread
PET-CT or CT of chest, abdomen and pelvis Looks for distant spread
Brain MRI Considered in many cases
Blood tests Blood count, kidney and liver function, sodium

Staging

Doctors use the FIGO staging system for cervical cancer.

Stage Simplified meaning
Stage I Confined to the cervix
Stage II Spread beyond the cervix to the upper vagina or tissues beside the womb, but not to the pelvic wall
Stage III Spread to the lower vagina, pelvic wall or pelvic or para-aortic lymph nodes, or blocking a kidney
Stage IV Spread to the bladder or bowel, or to distant organs

In the review, about half of all women were diagnosed at an early stage and half at a late stage (Tempfer et al., 2018).

7. Treatment

There are no randomised trials for this rare cancer. Treatment is based on case series, expert guidelines and experience with small cell lung cancer. It should be planned by a gynaecological oncology team.

Main approaches

Stage Common approach
Early stage, small tumour Radical hysterectomy with lymph node removal, followed by etoposide-platinum chemotherapy, with or without radiotherapy
Early stage, larger tumour Chemotherapy first, then surgery, or chemoradiotherapy
Locally advanced Chemoradiotherapy with etoposide-platinum, often followed by further chemotherapy; surgery in selected women
Metastatic Etoposide-platinum chemotherapy; immunotherapy or trials
Recurrent Other chemotherapy regimens such as topotecan, paclitaxel and bevacizumab; trials

Chemotherapy

The most widely used regimen is cisplatin or carboplatin with etoposide, the same combination used for small cell lung cancer (Tempfer et al., 2018).

Aspect Details
Drugs Cisplatin or carboplatin plus etoposide
Number of cycles Usually 4-6
Timing Before or after surgery, or with radiotherapy

Surgery

A study combining data from US and Chinese registries found that surgery was linked to better survival, including in some women with locally advanced disease (Chu et al., 2023). This differs from common cervical cancer, where larger tumours are usually treated with chemoradiotherapy alone.

Radiotherapy

Type Use
External beam radiotherapy Treats the pelvis and lymph nodes
Brachytherapy Internal radiotherapy placed in the cervix or vagina
Brain radiotherapy For brain spread; preventive treatment is sometimes discussed

An Italian study of 27 women having surgery and chemotherapy found that adding brachytherapy was linked to better survival (Valenza et al., 2023).

Immunotherapy

Checkpoint inhibitors work in small cell lung cancer and in common cervical cancer. Their role in small cell cervical cancer is still being studied, and evidence so far comes from case reports (Chao et al., 2023).

Side effects

Treatment Possible side effects
Radical hysterectomy Loss of fertility, bladder problems, leg swelling after node removal
Etoposide-platinum Hair loss, low blood counts, infection risk, sickness, numbness, hearing changes
Pelvic radiotherapy Diarrhoea, bladder irritation, vaginal narrowing, early menopause
Immunotherapy Inflammation of the skin, gut, liver, lungs or hormone glands

Fertility and menopause

Treatment usually ends the possibility of pregnancy and causes early menopause in younger women. Ask your team about fertility preservation and hormone replacement. Unlike some hormone-sensitive cancers, HRT is often considered safe after treatment for cervical cancer, but discuss it with your oncologist.

8. Outlook (prognosis)

The outlook is more guarded than for common cervical cancer at the same stage.

Source Main finding
Systematic review, more than 3,500 cases Average survival around 40 months; average time free of recurrence about 16 months (Tempfer et al., 2018)
Italian series, 27 women having surgery Median overall survival 33 months (Valenza et al., 2023)
US and Chinese registries, 1,288 women Surgery linked to longer survival (Chu et al., 2023)

Factors that affect the outlook

Factor Effect
Stage The most important factor
Tumour size Smaller tumours do better
Lymph node spread Poorer outlook
Complete treatment Women who finish combined treatment do better

9. Follow-up

Period Typical checks
Years 1-2 Every 3 months: examination and scans as advised
Years 3-5 Every 6 months
After 5 years Yearly

Scans are often used more often than for common cervical cancer because of the higher risk of distant spread.

10. Living with small cell neuroendocrine carcinoma of the cervix

  • Use vaginal dilators after radiotherapy if advised, to reduce narrowing
  • Report new symptoms such as headaches, cough or bone pain promptly
  • Look after your bones and heart if you have early menopause
  • Stop smoking, which also helps healing and recovery
  • Ask for psychosexual support if sex has become difficult
  • Seek support from gynaecological cancer charities

Coping with the diagnosis

Hearing that you have a rare, fast-growing cancer can be frightening, particularly for younger women who may be caring for children or planning a family. Specialist gynaecological oncology nurses can explain each step of treatment and help you plan around it. Psychological support, peer support groups and financial advice services are available through most cancer centres.

11. Frequently asked questions

Question Answer
Is this the same as small cell lung cancer? No, it starts in the cervix, but it behaves similarly and is treated in a similar way
Why did my smear test not find it? It often grows inside the canal and sheds few abnormal cells
Is it caused by HPV? Usually, yes
Can I have children after treatment? Usually not; discuss options before treatment
Do I need a brain scan? Many teams recommend one because brain spread is more common than in other cervical cancers
Is immunotherapy an option? It is being studied; ask about trials
Will I need chemotherapy even if surgery removes everything? Usually yes, because hidden cancer cells may already have spread
Is it more common in older women? No; it often affects younger women than other gynaecological cancers do

12. Questions to ask your care team

  • Is my cancer small cell or large cell neuroendocrine carcinoma?
  • What stage is it, and has it spread?
  • Do I need a brain MRI?
  • Will I have surgery, chemoradiotherapy or both?
  • Which chemotherapy do you recommend, and for how long?
  • How will treatment affect my fertility, menopause and sex life?
  • Are there clinical trials I could join?

Resources

  1. Chao, A. et al. (2023) ‘Small cell neuroendocrine carcinoma of the cervix: from molecular basis to therapeutic advances’, Biomedical Journal, 46(5), 100633.
  2. Chu, T. et al. (2023) ‘The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry’, Lancet Oncology, 24(6), pp. 701-708.
  3. Tempfer, C.B. et al. (2018) ‘Neuroendocrine carcinoma of the cervix: a systematic review of the literature’, BMC Cancer, 18(1), 530.
  4. Valenza, C. et al. (2023) ‘Multimodal treatment for resectable neuroendocrine carcinoma of the cervix’, Endocrine-Related Cancer, 30(10), e230112.
  5. National Cancer Institute (2026) Cervical Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/cervical/hp/cervical-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.